Business Description
Modalis Therapeutics Corp
ISIN : JP3922600006
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 7.87 | |||||
Equity-to-Asset | 0.79 | |||||
Debt-to-Equity | 0.15 | |||||
Debt-to-EBITDA | -0.08 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -74.5 | |||||
3-Year EPS without NRI Growth Rate | -64.9 | |||||
3-Year FCF Growth Rate | -17.4 | |||||
3-Year Book Growth Rate | -42.5 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 20.75 | |||||
9-Day RSI | 34.86 | |||||
14-Day RSI | 41.68 | |||||
3-1 Month Momentum % | 41.3 | |||||
6-1 Month Momentum % | 83.1 | |||||
12-1 Month Momentum % | 7.44 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 12.91 | |||||
Quick Ratio | 12.87 | |||||
Cash Ratio | 12.38 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.4 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -133.46 | |||||
ROA % | -106.66 | |||||
ROIC % | -921.5 | |||||
3-Year ROIIC % | 287.21 | |||||
ROC (Joel Greenblatt) % | -4509.58 | |||||
ROCE % | -116.77 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 4 | |||||
Price-to-Tangible-Book | 3.93 | |||||
EV-to-EBIT | -2.43 | |||||
EV-to-EBITDA | -2.43 | |||||
EV-to-FCF | -2.38 | |||||
Price-to-Net-Current-Asset-Value | 4.23 | |||||
Price-to-Net-Cash | 4.46 | |||||
Earnings Yield (Greenblatt) % | -41.2 | |||||
FCF Yield % | -36.48 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Modalis Therapeutics Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil 円) | |||
EPS (TTM) (円) | -64.98 | ||
Beta | 0.71 | ||
3-Year Sharpe Ratio | -0.21 | ||
3-Year Sortino Ratio | -0.46 | ||
Volatility % | 158.86 | ||
14-Day RSI | 41.68 | ||
14-Day ATR (円) | 9.926034 | ||
20-Day SMA (円) | 127.65 | ||
12-1 Month Momentum % | 7.44 | ||
52-Week Range (円) | 62 - 203 | ||
Shares Outstanding (Mil) | 56.65 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Modalis Therapeutics Corp Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Modalis Therapeutics Corp Stock Events
Event | Date | Price (円) | ||
---|---|---|---|---|
No Event Data |
Modalis Therapeutics Corp Frequently Asked Questions
What is Modalis Therapeutics Corp(TSE:4883)'s stock price today?
When is next earnings date of Modalis Therapeutics Corp(TSE:4883)?
Does Modalis Therapeutics Corp(TSE:4883) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |